Gyre Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
Monitoring Framework
Key Performance Indicators
ETUARY (pirfenidone) Sales Quarterly21MTarget: Maintain market leadership in China pulmonary fibrosis market
Etorel (nintedanib ethanesulfonate) Sales Quarterly700KTarget: Expand national procurement and market access in China
F351 (hydronidone) Regulatory Progress AnnuallyTarget: Conditional approval by China NMPA for CHB-induced liver fibrosis
Watch Items
- F351 (hydronidone) China NMPA NDA ReviewTrigger: NMPA conditional approval decisionAction: Initiate commercial launch preparations in China and scale up manufacturing
- F351 (hydronidone) U.S. IND Application for MASH-associated liver fibrosisTrigger: IND clearance by the U.S. FDAAction: Initiate Phase 2 clinical trial in the United States
- Integration of Cullgen Inc. AcquisitionTrigger: Successful pipeline advancement of targeted protein degradersAction: Monitor R&D spend and clinical trial milestones for CDK2/Cyclin E and TYK2/JAK1 programs
Research as of 19 Jun 2026